Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Depression in cancer patients is common, is often untreated, but can be significantly improved with a new, integrated approach to care, NIHR CLAHRC Oxford part-funded research in The Lancet has revealed.

This trial shows that we can effectively treat depression in patients with poor prognosis cancers like lung cancer and really improve patients’ lives.”
- Dr Jane Walker, Senior Clinical Researcher, University of Oxford and NIHR CLAHRC Oxford comorbidity theme researcher.

Researchers from the Universities of Oxford and Edinburgh looked at the prevalence of major depression in more than 20,000 Scottish cancer patients through three separate studies.

They found that depression was substantially more common in cancer patients than the general population, yet only around a quarter of patients were receiving treatment.

The researchers also found that depressed cancer patients receiving a new treatment programme (Depression Care for People with Cancer, DCPC) had a ‘strikingly’ increased response to treatment compared with those who were given usual care.  

Other cancer-related symptoms - including anxiety, pain and fatigue - were also improved by the treatment, as was quality of life. The cost of the treatment programme was modest in comparison with other treatments. 

Lung cancer patients were the most affected, with around one in eight patients being diagnosed with depression. Depression was also more common in women, younger patients and those from socially deprived backgrounds.

One of the three studies looked at 500 people with a positive cancer prognosis who also suffered from major depression. Doctors found that after six months, 62 per cent of patients who received the integrated care programme responded to treatment compared with just 17 per cent of those who received standard care. This benefit was also seen 12 months after treatment.

In a separate study of 142 lung cancer patients, patients who received the integrated care programme had a significantly greater improvement in depression compared with those receiving existing treatments, enhancing their quality of life.

The new programme, DCPC, is an intensive approach. All patients are offered both antidepressants and psychological therapy.

The treatment is delivered by a team of specialist cancer nurses and supervising psychiatrists, who work in collaboration with the patient’s oncology team and GP. Most sessions are delivered face-to-face.

Michael Sharpe, Professor of Psychological Medicine, University of Oxford and NIHR CLAHRC Oxford comorbidity theme lead, who led the study, commented:

“The huge benefit that DCPC delivers for patients with cancer and depression shows what we can achieve for patients if we take as much care with the treatment of their depression as we do with the treatment of their cancer.”

Co-author Dr Jane Walker, Senior Clinical Researcher, University of Oxford and NIHR CLAHRC Oxford comorbidity theme researcher, said:

“Patients with lung cancer often have a poor prognosis. If they also have major depression that can blight the time they have left to live. This trial shows that we can effectively treat depression in patients with poor prognosis cancers like lung cancer and really improve patients’ lives.”

The findings of the three studies are published in journals The Lancet, The Lancet Oncology and The Lancet Psychiatry. The research was funded by Cancer Research UK, The Chief Scientist Office of the Scottish Government and the NIHR CLAHRC Oxford.

Podcast

In The Lancet's podcast, Naomi Lee discusses the research with Michael Sharpe and Jane Walker. 

Michael Sharpe interview on BBC Radio 4 Today programme.

Sign-up for our newsletter

Keep up-to-date with the latest news, events and publications. 

Similar stories

Low calorie meal replacements are a cost-effective routine treatment for obesity in the NHS

CLAHRC Research

NIHR CLAHRC Oxford supported Researchers: Replacing all regular meals with a low calorie diet of soups, shakes and bars, together with behavioural support, is cost-effective as a routine treatment for obesity

Only “modest” improvement in heart failure survival rates since 2000

CLAHRC Partner Research

Research led by Dr Clare Taylor and CLAHRC Oxford Director Professor Richard Hobbs finds that survival after a diagnosis of heart failure in the United Kingdom has shown only modest improvement in the 21st century and lags behind other serious conditions, such as cancer, in a large study published by The BMJ today.

Moderate to high intensity exercise does not slow cognitive decline in people with dementia

CLAHRC Partner Research

New research supported by CLAHRC Oxford and led by CLAHRC Oxford Theme 2 lead, Professor Sallie Lamb, suggests that while exercise can improve the fitness of people with dementia it does not slow their cognitive decline.

Presenting evidence to the All-Party Parliamentary Group on Suicide and Self-harm Prevention

CLAHRC Partner Research

CLAHRC Oxford supported researchers were recently invited to present evidence to the ‘suicide and self-harm’ All-party Parliamentary Group (APPG). The group were surprised and impressed by the evidence presented and intend to forward it to the Minister for Health and Social Care, Jeremy Hunt.

CLAHRC Oxford Infographic Shortlisted for NIHR Digital Award

CLAHRC Public engagement Research

A CLAHRC Oxford infographic, produced to share the preliminary results of the OxFAB study with participants of the study, has been shortlisted as part of the NIHR’s Let’s Get Digital competition.

Oxford Health NHS Foundation Trust tops table of recruitment for research

Partner Research

NIHR CLAHRC Oxford's host NHS trust has risen to the top of a table for the most people recruited to take part in research studies.